Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

C
Cacovean, Alex

Biomea Fusion
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Alex Cacovean
Favorite
CADOT, Sarah

CRCT/INSERM/CNRS+UPS
4002 - Longitudinal CITE-Seq analyses of the peripheral blood identify transcriptomic signatures associated with progression and transformation under targeted therapy
Sarah CADOT
Favorite
Caiolfa, Valeria
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Valeria Caiolfa
Favorite
Calleja, Anne

Institut Paoli Calmettes
1211 - Venetoclax as an Alternative and Effective Treatment in Central Nervous System Involvement of Chronic Lymphocytic Leukemia: Monocentric Experience
Anne Calleja
Favorite
Call, Timothy

Mayo Clinic
1121 - Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents
Timothy Call
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Timothy Call
Favorite
Campanella, Alessandro

Vita-Salute San Raffaele University
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Alessandro Campanella
Favorite
Campanile, Riccardo
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Riccardo Campanile
Favorite
Campo, Elias

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Elias Campo
Favorite
Candoni, Anna

Università degli Studi di Modena e Reggio Emilia
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Anna Candoni
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Anna Candoni
Favorite
Cannata, Jimena

Hospital Universitario de la Princesa
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Jimena Cannata
Favorite
Capasso, Antonella

IRCCS Ospedale San Raffaele
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Antonella Capasso
Favorite
Capasso, Guido

University of Padua
1016 - DEFACTINIB AFFECTS CHRONIC LYMPHOCYTIC LEUKEMIA CELL SURVIVAL WITH ADDITIVE EFFECT IN COMBINATION WITH BTK INHIBITORS
Guido Capasso
Favorite
Cardemil, Daniela

Magallanes Clinical Hospital
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Daniela Cardemil
Favorite
Cardillo, Martina

The Feinstein Institutes for Medical Research, Northwell Health
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Martina Cardillo
Favorite
1049 - Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome
Martina Cardillo
Favorite
Caroline, Protin
1114 - Pharmacokinetics of idelalisib and outcomes
Protin Caroline
Favorite
Carras, Sylvain
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Sylvain Carras
Favorite
Carter, Jason

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Jason Carter
Favorite
Cartron, Guillaume

Centre Hospitalier Universitaire de Montpellier
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Guillaume Cartron
Favorite
Carzavec, Dubravka

University Hospital Centre Sisters of Mercy
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Dubravka Carzavec
Favorite
Casan, Joshua

Peter MacCallum Cancer Centre and Royal Melbourne Hospital
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Joshua Casan
Favorite
Cassarino, Chiara

IMEX-CONICET-ANM
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Chiara Cassarino
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Chiara Cassarino
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Chiara Cassarino
Favorite
Cassina, Valeria
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Valeria Cassina
Favorite
Cass, Samuel

University of Texas MD Anderson Cancer Center
1137 - Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)
Samuel Cass
Favorite
Castaño, Jose Luis

Instituto de Investigación Marqués de Valdecilla (IDIVAL)
1043 - Regulation of the NF-kB pathway by NEDDylation in chronic lymphocytic leukemia: Beyond IkB
Jose Luis Castaño
Favorite
Castells, Oriol

Vall d'Hebron Institute of Oncology (VHIO)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Oriol Castells
Favorite
Castilla Llorente, Cristina

Institut Gustave Roussy
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Cristina Castilla Llorente
Favorite
Catania, Gioacchino

Division of Hematology, Hospital Saints (A. O. SS) Antonio e Biagio and Cesare Arrigo
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Gioacchino Catania
Favorite
Ceccarelli, Matteo

Eli Lilly and Company
2008 - BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Matteo Ceccarelli
Favorite
CERAPIO, Juan-Pablo

CRCT/INSERM/CNRS+UPS
4002 - Longitudinal CITE-Seq analyses of the peripheral blood identify transcriptomic signatures associated with progression and transformation under targeted therapy
Juan-Pablo CERAPIO
Favorite
Chabowska, Maria

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Maria Chabowska
Favorite
Chanan-Khan, Asher

Department of Cancer Biology, Mayo Clinic and Mayo Clinic Cancer Center at St. Vincent’s Medical Center Riverside
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Asher Chanan-Khan
Favorite
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Asher Chanan-Khan
Favorite
Chang, Amy E.

Loxo Oncology at Lilly
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Amy E. Chang
Favorite
Chang, Naomi
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Naomi Chang
Favorite
Chan, Julie

King's College London
1012 - High-dimensional Single-cell Characterisation of the Chronic Lymphocytic Leukaemia Tumour Microenvironment using Imaging Mass Cytometry
Julie Chan
Favorite
Chaoui, Driss

Service Hématologie, CH Argenteuil
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Driss Chaoui
Favorite
Chapiro, Elise

Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Elise Chapiro
Favorite
Charalampopoulou, Stella

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Stella Charalampopoulou
Favorite
Chatelut, Etienne
1114 - Pharmacokinetics of idelalisib and outcomes
Etienne Chatelut
Favorite
Chatzidimitriou, Anastasia
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Anastasia Chatzidimitriou
Favorite
Chavez, Julio

H Lee Moffitt Cancer Center & Research Institute
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Julio Chavez
Favorite
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Julio Chavez
Favorite
Cheah, Chan Y.

Linear Clinical Research and Sir Charles Gairdner Hospital and University of Western Australia
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Chan Y. Cheah
Favorite
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Chan Y. Cheah
Favorite
Chebrek, Safia
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Safia Chebrek
Favorite
Chen, Hong

AstraZeneca
1220 - Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials (RCTs)
Hong Chen
Favorite
Chen, Jianyong

Ascentage Pharma (Suzhou) Co., Ltd.
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Jianyong Chen
Favorite
Chen, Jiawen

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Jiawen Chen
Favorite
Chen, Lu

City of Hope National Medical Center
1210 - A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Lu Chen
Favorite
Chen, Shih-Shih

Feinstein Institute for Medical Research
1049 - Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome
Shih-Shih Chen
Favorite
1054 - The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Shih-Shih Chen
Favorite
Chen, Xi

Fujian Institute of Hematology, Fujian Medical University Union Hospital
1107 - Mechanisms of differential response to BTKi targeted therapy in patients with chronic lymphocytic leukemia
Xi Chen
Favorite
Chen, Xiao
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Xiao Chen
Favorite
Chen, YuJu

Northwell Health
1049 - Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome
YuJu Chen
Favorite
Chen, Zi

Ascentage Pharma (Suzhou) Co., Ltd.
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Zi Chen
Favorite
Cheson, Bruce

Lymphoma Research Foundation
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Bruce Cheson
Favorite
Chiarenza, Annalisa

Division of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Annalisa Chiarenza
Favorite
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Annalisa Chiarenza
Favorite
Chiodin, Giorgia

Cancer Sciences, Faculty of Medicine, University of Southampton
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Giorgia Chiodin
Favorite
Chiorazzi, Nicholas

The Feinstein Institutes for Medical Research, Northwell Health
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Nicholas Chiorazzi
Favorite
1021 - Transcriptional correlation analysis of the CD180/MD-1 complex and toll-like receptors and signaling lymphocyte activation family receptors in chronic lymphocytic leukemia.
Nicholas Chiorazzi
Favorite
1049 - Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome
Nicholas Chiorazzi
Favorite
1054 - The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Nicholas Chiorazzi
Favorite
Chiriu, Sabrina

Department of Medical Sciences and Public Health, University of Cagliari
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Sabrina Chiriu
Favorite
Choi, Michael

Moores Cancer Center, University of California San Diego
1115 - Venetoclax Consolidation after BTKi Based Therapy for Patients with CLL
Michael Choi
Favorite
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Michael Choi
Favorite
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Michael Choi
Favorite
Choi, Yun

Tufts Medical Center, Boston, MA, USA
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Yun Choi
Favorite
Choma, Morgan

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Morgan Choma
Favorite
Chong, Stephen

Dana Farber Cancer Institute
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Stephen Chong
Favorite
Christensen, Rita

LYLE - Patient organisation for lymphoma, leukaemia, MDS
1108 - Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia
Rita Christensen
Favorite
Chu, Charles

Wilmot Cancer Institute / University of Rochester Medical Center
1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)
Charles Chu
Favorite
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Charles Chu
Favorite
Chung, Gina

The Christ Hospital, Lindner Center for Research and Education
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Gina Chung
Favorite
Chyla, Brenda

AbbVie Inc.
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Brenda Chyla
Favorite
Ciccio, Gina

Department of Cancer Biology, Mayo Clinic
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Gina Ciccio
Favorite
Ciccolini, Joseph

CHU Timone
1211 - Venetoclax as an Alternative and Effective Treatment in Central Nervous System Involvement of Chronic Lymphocytic Leukemia: Monocentric Experience
Joseph Ciccolini
Favorite
Ciepluch, Hanna

Department of Hematology, Copernicus Regional Oncology Centre
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Hanna Ciepluch
Favorite
Ciuban, Georgeta

University of Oxford, Department of Oncology
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Georgeta Ciuban
Favorite
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Georgeta Ciuban
Favorite
Clavert, Aline

Service Hématologie, CHU Angers
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Aline Clavert
Favorite
Coates, Elisabeth

Oncternal Therapeutics
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Elisabeth Coates
Favorite
Coelho, Mariana

German Cancer Research Center
1057 - Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Mariana Coelho
Favorite
Coha, Bozena

General Hospital Dr. Josip Bencevic, Slavonski Brod
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Bozena Coha
Favorite
Cohen, Aileen

BeiGene USA, Inc.
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Aileen Cohen
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Aileen Cohen
Favorite
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Aileen Cohen
Favorite
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Aileen Cohen
Favorite
Cohen, Jonathan

Fred Hutchinson Cancer Center / UW Medicine
1106 - Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Jonathan Cohen
Favorite
Colado, Ana

IMEX-CONICET-ANM
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Ana Colado
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Ana Colado
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Ana Colado
Favorite
Collignon, Aude

Department of Hematology, Institut Paoli-Calmettes
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Aude Collignon
Favorite
Collins, Graham

Oxford University Hospitals Foundation NHS Trust
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Graham Collins
Favorite
Collins, Mary

Department of Medical Oncology, Dana-Farber Cancer Institute
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Mary Collins
Favorite
Colomer, Dolors

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Dolors Colomer
Favorite
Comba, Lorenzo

1 Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3,10126, Torino, Italy
2 Department of Molecular Biotechnology and Health Sciences, University of Torino
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Lorenzo Comba
Favorite
Coombs, Catherine C.

University of California Irvine
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Catherine C. Coombs
Favorite
2008 - BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Catherine C. Coombs
Favorite
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Catherine C. Coombs
Favorite
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Catherine C. Coombs
Favorite
Copland, John

Department of Cancer Biology, Mayo Clinic
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
John Copland
Favorite
Corchete Sánchez, Luis A.

Massachusetts General Hospital Center for Cancer Research, Charlestown, MA 02129; Harvard Medical School, Boston, MA 02215; Broad Institute of MIT and Harvard, Cambridge, MA 02139
1161 - ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
Luis A. Corchete Sánchez
Favorite
Cordini, Gregorio

Laboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Gregorio Cordini
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Gregorio Cordini
Favorite
Cordoba, Raul

Fundación Jiménez Díaz
1116 - SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE
Raul Cordoba
Favorite
Correa, Agustin

Institut Pasteur de Montevideo
1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Agustin Correa
Favorite
Corry, Anthony J.

AstraZeneca
1220 - Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials (RCTs)
Anthony J. Corry
Favorite
Coscia, Marta

Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3,10126, Torino, Italy2 Department of Molecular Biotechnology and Health Sciences, University of Torino
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Marta Coscia
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Marta Coscia
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Marta Coscia
Favorite
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Marta Coscia
Favorite
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Marta Coscia
Favorite
Cosentino, Chiara
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Chiara Cosentino
Favorite
Cramer, Paula

Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Paula Cramer
Favorite
Crescenzo, Rocco

BeiGene USA, Inc.
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Rocco Crescenzo
Favorite
Crespo, Marta

Vall d'Hebron Institute of Oncology (VHIO)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Marta Crespo
Favorite
Cretenet, Gaspard

1 Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam institute for Infection and Immunity, Amsterdam, The Netherlands; 2 Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands
1044 - T cells from chronic lymphocytic leukemia patients are not exhausted but show signs of senescence, providing alternative clues for improvement
Gaspard Cretenet
Favorite
Crispatzu, Giuliano
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Giuliano Crispatzu
Favorite
Cull, Gavin

Austin Hospital
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Gavin Cull
Favorite
Curnow, Jenny

Concord Hospital
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Jenny Curnow
Favorite
Custidiano, Rosario

Instituto Alexander Fleming
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Rosario Custidiano
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Rosario Custidiano
Favorite
Cutts, Anthony

Oxford Molecular Diagnostics Centre
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Anthony Cutts
Favorite
Cymbalista, Florence

Hôspital Avicienne
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Florence Cymbalista
Favorite
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Florence Cymbalista
Favorite